Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis

•Immune checkpoint inhibitors are a rapidly evolving treatment regime used for various cancer therapies. The role of other medications in their effectiveness remains conflicted. Proton Pump Inhibitors are one of the most commonly prescribed medications and are particularly often prescribed to cancer patients.•Our study finds that Proton Pump Inhibitors worsen the outcomes of overall survival and increase risk of disease progression in Non-Small Cell Lung Carcinoma.•We hope that this study will enlighten providers to use proton pump inhibitors more judiciously in patients with Non-Small Cell Lung Carcinoma.